Abstract
Forty patients with tinea pedis were treated for six weeks in a double-blind study with a tolciclate or placebo solution. The tolciclate solution demonstrated moderate efficacy compared with placebo. The finding of positive KOH preparations in a significant number of tolciclate-treated patients with persistently negative cultures suggests that the vehicle used (polyethylene glycol-400) may not provide adequate penetration of this effective antifungal agent. No adverse effects were noted.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 694-699 |
| Number of pages | 6 |
| Journal | Clinical Therapeutics |
| Volume | 8 |
| Issue number | 6 |
| State | Published - 1986 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
Cite this
Efficacy of tolciclate solution in patients with tinea pedis. / Gomez, E. C.; Huntley, A. C.; Isseroff, Roslyn Rivkah; Tanji, J.
In: Clinical Therapeutics, Vol. 8, No. 6, 1986, p. 694-699.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Efficacy of tolciclate solution in patients with tinea pedis
AU - Gomez, E. C.
AU - Huntley, A. C.
AU - Isseroff, Roslyn Rivkah
AU - Tanji, J.
PY - 1986
Y1 - 1986
N2 - Forty patients with tinea pedis were treated for six weeks in a double-blind study with a tolciclate or placebo solution. The tolciclate solution demonstrated moderate efficacy compared with placebo. The finding of positive KOH preparations in a significant number of tolciclate-treated patients with persistently negative cultures suggests that the vehicle used (polyethylene glycol-400) may not provide adequate penetration of this effective antifungal agent. No adverse effects were noted.
AB - Forty patients with tinea pedis were treated for six weeks in a double-blind study with a tolciclate or placebo solution. The tolciclate solution demonstrated moderate efficacy compared with placebo. The finding of positive KOH preparations in a significant number of tolciclate-treated patients with persistently negative cultures suggests that the vehicle used (polyethylene glycol-400) may not provide adequate penetration of this effective antifungal agent. No adverse effects were noted.
UR - http://www.scopus.com/inward/record.url?scp=0023024778&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023024778&partnerID=8YFLogxK
M3 - Article
C2 - 3791364
AN - SCOPUS:0023024778
VL - 8
SP - 694
EP - 699
JO - Clinical Therapeutics
JF - Clinical Therapeutics
SN - 0149-2918
IS - 6
ER -